ArticleCancer gene therapy2007

The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells.

L Kasman et al.PubMed ↗Publisher ↗

No numbers read from the abstract.